Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Dec 28;142(26):2327-2331.
doi: 10.1182/blood.2023021274.

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

David A Qualls  1 , Nicholas Lambert  2 , Paolo F Caimi  3 , Mwanasha Merrill  4 , Priyanka Pullarkat  5 , Richard C Godby  6 , David A Bond  7 , Graham T Wehmeyer  8 , Jason Romancik  9 , Behzad Amoozgar  10 , Lori Leslie  11 , Loretta J Nastoupil  12 , Jennifer L Crombie  4 , Jeremy S Abramson  5 , Arushi Khurana  6 , Grzegorz S Nowakowski  6 , Kami Maddocks  7 , Sarah C Rutherford  8 , Brad Kahl  10 , Michelle Okwali  1 , Michael J Buege  1 , Venkatraman Seshan  1 , Connie L Batlevi  1 , Gilles Salles  1   13
Affiliations
Multicenter Study

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

David A Qualls et al. Blood. .

Abstract

In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: P.F.C. has received research funding from ADC Therapeutics, Genentech, and AbbVie and honoraria for participation in advisory boards/consulting from ADC Therapeutics, Beigene, BMS, Genentech, Kite, Lilly, MEI Pharma, Novartis, and Takeda. D.A.B. has received research funding from Incyte/Morphosys, Novartis, and Nurix Therapeutics and honoraria for consulting from SeaGen, Kite/Gilead, Nurix Therapeutics, and Novartis. L.L. has received honoraria for consulting and/or participation in speaker bureau from Kite/Gilead, Beigene, Pharmacyclics, AbbVie, Genmab, SeaGen, Janssen, AstraZeneca, Eli Lilly, Epizyme, TG Therapeutics, Merck, and ADC Therapeutics. L.J.N. has received honoraria for participation in advisory boards/consulting from AbbVie, ADC Therapeutics, Atara Biotherapeutics, BMS/Celgene, Caribou Biosciences, Daiichi Sankyo, Epizyme, Genentech/Roche, Genmab, Janssen, Incyte, Morphosys, Novartis, and Takeda and research support from BMS/Celgene, Caribou Biosciences, Daiichi Sankyo, Epizyme, Genentech/Roche, Genmab, Gilead/Kite, IGM Biosciences, Janssen, Novartis, and Takeda. J.L.C. has received research support (to institution) from Genentech, Merck, Bayer, and AbbVie and honoraria for consulting from ADC Therapeutics, Kite Pharma, Genmab, and Incyte/MorphoSys. J.S.A. has received honoraria for consulting from AbbVie, AstraZeneca, BeiGene, BMS, Caribou Biosciences, Cellectar, Century Therapeutics, Epizyme, Genentech, Genmab, Incyte, Interius, Janssen, Kite Pharma, Kymera, Lilly, MorphoSys, Mustang Bio, Ono Pharma, Regeneron, and Takeda and research support (to institution) from BMS, Cellectis, Merck, Mustang Bio, and Seattle Genetics. G.S.N. has received honoraria for consultancy from AbbVie, ADC Therapeutics, Bantam Pharmaceutical LLC, Blueprint Medicines, Bristol Myers Squibb, Celgene Corporation, Curis, Debiopharm, F. Hoffmann-La Roche Limited, Fate Therapeutics, Genentech, Incyte, Karyopharm Therapeutics, Kite Pharma, Kymera Therapeutics, MEI Pharma, MorphoSys AG, Ryvu Therapeutics, Seagen, Selvita Inc, TG Therapeutics, and Zai Lab Limited and research funding from Bristol Myers Squibb and MorphoSys and is a member on a board of directors or advisory committee for Karyopharm Therapeutics, Ryvu Therapeutics, and Fate Therapeutics. K.M. has received research funding from Pharmacyclics, Novartis, Merck, BMS, and Celgene and honoraria for consulting from AbbVie, ADC Therapeutics, AstraZeneca, BMS, Celgene, Gilead/Kite, GenMab, Genentech, Incyte, Janssen, Merck, Morphosys, Lilly, and Pharmacyclics. S.C.R. has received research funding from Constellation, Karyopharm, and Genentech/Roche and honoraria for consulting from ADC, Genmab, Karyopharm, Kite, and Seagen. B.K. has received honoraria for consulting from AbbVie, AstraZeneca, ADCT, BeiGene, BMS, Genentech, Genmab, Gilead, Janssen, and Lilly and research funding from Genentech, ADCT, AstraZeneca, and BeiGene. C.L.B. is currently employed at Roche/Genentech; participation in the study occurred prior to employment at Roche/Genentech. G.S. has received, in the last 12 months, financial compensation for participating in advisory boards or consulting from AbbVie, ATB Therapeutics, Beigene, BMS/Celgene, Debiopharm, Genentech/Roche, Genmab, Incyte, Ipsen, Janssen, Kite/Gilead, Loxo/Lilly, Merck, Molecular Partners, Nordic Nanovector, Novartis, Nurix, and Orna; is shareholder of Owkin; and has received research support managed by his institution from Genentech, Janssen and Ipsen. The remaining authors declare no competing financial interests.

The current affiliation for C.L.B. is Roche/Genentech, San Francisco, CA.

Figures

Figure 1.
Figure 1.
Survival after TL therapy. PFS (A) and OS (B) after TL initiation for all patients receiving TL off-trial. Progression-free (C) and overall survival (D) stratified by L-MIND eligibility, excluding laboratory-based markers of renal, hepatic, and hematologic function. Tafa, tafasitamab.
See this image and copyright information in PMC

Comment in

References

    1. US Food and Drug Administration FDA grants accelerated approval to tafasitamab-cxix for diffuse large B-cell lymphoma. Last updated 3 August 2020. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accele...
    1. Delgado J, Papadouli I, Sarac SB, et al. The European Medicines Agency review of tafasitamab in combination with lenalidomide for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma. Hemasphere. 2021;5(12):e666. - PMC - PubMed
    1. Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978–988. - PubMed
    1. Duell J, Maddocks KJ, González-Barca E, et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021;106(9):2417–2426. - PMC - PubMed
    1. Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128(21):2489–2496. - PubMed

Publication types

MeSH terms

LinkOut - more resources